A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

By R. Belfort, S. Harrison, K. A. Brown, Celia Darland, J. Finch, Jean Hardies, B. Balas, Amalia Gastaldelli, F. Tio, Joseph P Pulcini and 9 more. New England Journal of Medicine, 2006

1,769 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/564aeef63ee9f11de6e4025f81b09d03c31d9fe1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. S. Klein
4. A. Okunade
5. B. Patterson
6. K. Cusi
7. C. Day
8. A. Sanyal

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. E. Brunt
6. C. Day
7. S. Bellentani
8. S. Klein

In Physiology

1. K. Cusi
2. Gerald I. Shulman
3. V. Samuel
4. Asociacion Latinoamericana para el Estudio del Higado

Citations in the corpus

• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Five randomized controlled trials are available [203–207], which are heterogenous for drugs and dosages, duration of treatment, categories of patients included and histological outcomes [208].”
• Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. (2011, background): “Efficacy of drug therapies in major trials is assessed as changes in 6-month or 1-year biopsies [60], whereas elastography studies have included patients with as long as a 3-year interval between tests, making comparisons meaningless [61].”
• Current and future pharmacological therapies for NAFLD/NASH (2017, background): “PPARc Two randomized, double-blind, placebo-controlled trials (RDBPCT) have shown that pioglitazone [peroxisome proliferator-activated receptor gamma (PPARc) agonist] significantly ameliorated steatosis and necroinflammation compared to placebo in diabetic NASH [24, 25].”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “(18,25-27) It is also important to remember the importance of bidirectional association between NAFLD and T2DM.”
• Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus (2016, neutral): “Additional secondary outcomes included the following: 1) fasting plasma glucose, fasting plasma insulin, FFA, hemoglobin A1c, fasting plasma lipid profile, adiponectin, and cytokeratin-18 concentrations; 2) total body fat percentage, measured by DXA; 3) hepatic triglyceride content, measured by magn”
• Hepatic fibrosis: Concept to treatment. (2015, neutral): “plac; 6 mo, r, db No effect 2006 4 55 [61]”
• Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity (2009, background): “The potential importance of CD36 in regulating insulin sensitivity is supported by studies conducted in animal models and in obese and diabetic human subjects that found increased plasmalemma skeletal muscle CD36 was associated with increased FFA uptake and insulin resistance (25, 30, 31) (even thou”